New Product Enables Company to Target Additional Surgical Procedures and Deepen Market Penetration in the Growing $1B Surgical Recovery Market MARIETTA, Ga., Sept. 19, 2022 MiMedx Group, Inc.. | September 19, 2022
Provides Favorable Access to a New $500 Million Market for the Treatment of Refractory Diabetic and Venous Ulcers for EPIFIX – the First and Only Amniotic.
MIMEDX Announces Second Quarter 2022 Operating and Financial Results apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Recommends Shareholders Vote “FOR” Both of MIMEDX’s Highly Qualified Director Nominees – James L. Bierman and Phyllis Gardner, M.D. Recommends Shareholders Vote. | May 20, 2022